The agreement with Carl Zeiss Meditec includes the acquisition of the production site of Mydriasert located in La Rochelle, France along with relevant staff.
Mydriasert allows to obtain an effective and stable mydriasis with one simple medical act helping to avoid repeat installations of different mydriatic eye drops either for surgical procedures or diagnostic purposes.
Mydriasert device, shaped like an oblong tablet, is applied beneath the eyelid which disperses phenylephrin hydrochlorid, for increasing pupil diameter with its alpha-sympathomimetic activity, and also disperses tropicamide, whose anti-cholinergic activity prevents the iris from contracting.
Laboratoires Thea COO Jean-Frederic Chibret said that the acquisition represents a significant addition to their product range and is completely in line with their strategy to become a leading provider of ophthalmic products.
“Our goal is to meet the needs of ophthalmologists in all major therapeutic classes so that we can be their daily partners, whatever their type of practice, and notably in ocular surgery,” Chibret said.
